27338800|t|NLRC5 promotes cell proliferation via regulating the AKT / VEGF-A signaling pathway in hepatocellular carcinoma
27338800|a|NLRC5, a newly found member of the NLR family and the largest member of nucleotide-binding, has been reported to regulate immune responses and is associated with hepatocellular carcinoma (HCC). We investigated the mechanisms and signaling pathways of NLRC5 in HCC progression. Increased expression of NLRC5, vascular endothelial growth factor-A (VEGF-A) were found in human HCC tissue. There was a positive correlation between NLRC5 and VEGF-A expression and cell proliferation were enhanced in NLRC5 - overexpressing HepG2 cells, but inhibited in cells with NLRC5 silencing treatment. Interestingly, we found that up-regulation of NLRC5 also coordinated the activation of PI3K/AKT signaling pathway. An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5 - overexpressing HepG2 cells. These results demonstrate that NLRC5 promotes HCC progression via the AKT / VEGF-A signaling pathway.
27338800	0	5	NLRC5	T103	UMLS:C2932687
27338800	15	33	cell proliferation	T038	UMLS:C0596290
27338800	53	56	AKT	T038	UMLS:C1515844
27338800	59	83	VEGF-A signaling pathway	T038	UMLS:C3271788
27338800	87	111	hepatocellular carcinoma	T038	UMLS:C2239176
27338800	112	117	NLRC5	T103	UMLS:C2932687
27338800	147	157	NLR family	T103	UMLS:C4277661
27338800	184	202	nucleotide-binding	T038	UMLS:C1148916
27338800	213	221	reported	T170	UMLS:C0684224
27338800	234	250	immune responses	T038	UMLS:C0301872
27338800	274	298	hepatocellular carcinoma	T038	UMLS:C2239176
27338800	300	303	HCC	T038	UMLS:C2239176
27338800	341	359	signaling pathways	T038	UMLS:C0037080
27338800	363	368	NLRC5	T103	UMLS:C2932687
27338800	372	375	HCC	T038	UMLS:C2239176
27338800	376	387	progression	T038	UMLS:C0178874
27338800	399	409	expression	T038	UMLS:C1171362
27338800	413	418	NLRC5	T103	UMLS:C2932687
27338800	420	456	vascular endothelial growth factor-A	T103	UMLS:C0078058
27338800	458	464	VEGF-A	T103	UMLS:C0078058
27338800	480	485	human	T204	UMLS:C0086418
27338800	486	489	HCC	T038	UMLS:C2239176
27338800	490	496	tissue	T017	UMLS:C0040300
27338800	510	518	positive	T033	UMLS:C1446409
27338800	539	544	NLRC5	T103	UMLS:C2932687
27338800	549	555	VEGF-A	T103	UMLS:C0078058
27338800	556	566	expression	T038	UMLS:C1171362
27338800	571	589	cell proliferation	T038	UMLS:C0596290
27338800	607	612	NLRC5	T103	UMLS:C2932687
27338800	615	629	overexpressing	T038	UMLS:C1514559
27338800	630	641	HepG2 cells	T017	UMLS:C2717940
27338800	660	665	cells	T017	UMLS:C0007634
27338800	671	676	NLRC5	T103	UMLS:C2932687
27338800	677	686	silencing	T038	UMLS:C0598496
27338800	727	740	up-regulation	T038	UMLS:C0041904
27338800	744	749	NLRC5	T103	UMLS:C2932687
27338800	816	838	AKT inhibitor LY294002	T103	UMLS:C0251991
27338800	847	853	VEGF-A	T103	UMLS:C0078058
27338800	854	864	expression	T038	UMLS:C1171362
27338800	869	872	AKT	T103	UMLS:C0164786
27338800	873	888	phosphorylation	T038	UMLS:C1158886
27338800	892	903	HepG2 cells	T017	UMLS:C2717940
27338800	908	913	NLRC5	T103	UMLS:C2932687
27338800	916	930	overexpressing	T038	UMLS:C1514559
27338800	931	942	HepG2 cells	T017	UMLS:C2717940
27338800	975	980	NLRC5	T103	UMLS:C2932687
27338800	990	993	HCC	T038	UMLS:C2239176
27338800	994	1005	progression	T038	UMLS:C0178874
27338800	1014	1017	AKT	T038	UMLS:C1515844
27338800	1020	1044	VEGF-A signaling pathway	T038	UMLS:C3271788